Home / News / International / Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

x

Check Also

Indonesian President, wins 2nd term

Indonesian President, wins 2nd term

New Delhi, May 21 (Udaipur Kiran): Indonesia’s Joko Widodo has been re-elected ...

Trump blacklists Chinese Telecos as 5G War Intensifies

Trump blacklists Chinese Telecos as 5G War Intensifies

Washington : President Donald Trump issued an executive order declaring a national ...